Correlation Between Arcellx and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Arcellx and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcellx and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Arcellx and Crispr Therapeutics AG, you can compare the effects of market volatilities on Arcellx and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcellx with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcellx and Crispr Therapeutics.
Diversification Opportunities for Arcellx and Crispr Therapeutics
0.49 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Arcellx and Crispr is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Arcellx and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Arcellx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcellx are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Arcellx i.e., Arcellx and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Arcellx and Crispr Therapeutics
Given the investment horizon of 90 days Arcellx is expected to generate 0.91 times more return on investment than Crispr Therapeutics. However, Arcellx is 1.1 times less risky than Crispr Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.02 per unit of risk. If you would invest 2,782 in Arcellx on November 28, 2024 and sell it today you would earn a total of 3,348 from holding Arcellx or generate 120.35% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Arcellx vs. Crispr Therapeutics AG
Performance |
| Timeline |
| Arcellx |
| Crispr Therapeutics |
Arcellx and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Arcellx and Crispr Therapeutics
The main advantage of trading using opposite Arcellx and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcellx position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.| Arcellx vs. Nuvalent | Arcellx vs. Ventyx Biosciences | Arcellx vs. Amylyx Pharmaceuticals | Arcellx vs. Day One Biopharmaceuticals |
| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |